{"doi":"10.1126/scitranslmed.abm6420","title":"A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy","abstract":"<jats:p>The accumulation of immune-suppressive myeloid cells is a critical determinant of resistance to anti–programmed death-1 (PD-1) therapy in advanced clear cell renal cell carcinoma (ccRCC). In preclinical models, the tyrosine kinase inhibitor sitravatinib enhanced responses to anti–PD-1 therapy by modulating immune-suppressive myeloid cells. We conducted a phase 1-2 trial to choose an optimal sitravatinib dose combined with a fixed dose of nivolumab in 42 immunotherapy-naïve patients with ccRCC refractory to prior antiangiogenic therapies. The combination demonstrated no unexpected toxicities and achieved an objective response rate of 35.7% and a median progression-free survival of 11.7 months, with 80.1% of patients alive after a median follow-up of 18.7 months. Baseline peripheral blood neutrophil-to-lymphocyte ratio correlated with response to sitravatinib and nivolumab. Patients with liver metastases showed durable responses comparable to patients without liver metastases. In addition, correlative studies demonstrated reduction of immune-suppressive myeloid cells in the periphery and tumor microenvironment following sitravatinib treatment. This study provides a rationally designed combinatorial strategy to improve outcomes of anti–PD-1 therapy in advanced ccRCC.</jats:p>","journal":"Science Translational Medicine","year":2022,"id":629396,"datarank":0.6329261557764161,"base_score":4.219507705176107,"endowment":4.219507705176107,"self_citation_contribution":0.6329261557764161,"citation_network_contribution":0.0,"self_endowment_contribution":0.6329261557764161,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":67,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1165368,"name":"Sangeeta Goswami","orcid":"0000-0001-9201-4503","position":1,"is_corresponding":false},{"id":104767,"name":"Peter F. Thall","orcid":"0000-0002-7293-529X","position":2,"is_corresponding":false},{"id":293088,"name":"Xuemei Wang","orcid":"0000-0002-3516-0966","position":3,"is_corresponding":false},{"id":546980,"name":"Ying Yuan","orcid":"0000-0002-3922-9553","position":4,"is_corresponding":false},{"id":311967,"name":"Eric Jonasch","orcid":"0000-0003-0943-2806","position":5,"is_corresponding":false},{"id":104274,"name":"Jianjun Gao","orcid":"0000-0001-6138-4472","position":6,"is_corresponding":false},{"id":274681,"name":"Matthew T. Campbell","orcid":"0000-0003-1915-4491","position":7,"is_corresponding":false},{"id":274685,"name":"Amishi Y. Shah","orcid":"0000-0002-9007-0621","position":8,"is_corresponding":false},{"id":413097,"name":"Paul G. Corn","orcid":"0000-0002-4106-6335","position":9,"is_corresponding":false},{"id":452510,"name":"Alda L. Tam","orcid":"0000-0002-6065-1556","position":10,"is_corresponding":false},{"id":503494,"name":"Kamran Ahrar","orcid":"0000-0002-7800-2300","position":11,"is_corresponding":false},{"id":261719,"name":"Priya Rao","orcid":"0000-0001-5672-0961","position":12,"is_corresponding":false},{"id":689108,"name":"Kanishka Sircar","orcid":"0000-0001-9515-697X","position":13,"is_corresponding":false},{"id":1438078,"name":"Lorenzo Cohen","orcid":"0000-0001-7366-0518","position":14,"is_corresponding":false},{"id":567736,"name":"Sreyashi Basu","orcid":"0000-0002-5028-3833","position":15,"is_corresponding":false},{"id":839943,"name":"Fei Duan","orcid":"0000-0002-4659-0144","position":16,"is_corresponding":false},{"id":378494,"name":"Sonali Jindal","orcid":"0000-0002-3911-6815","position":17,"is_corresponding":false},{"id":860655,"name":"Yuwei Zhang","orcid":"0000-0002-7855-0710","position":18,"is_corresponding":false},{"id":1490155,"name":"Hong Chen","orcid":"0000-0003-2315-0645","position":19,"is_corresponding":false},{"id":634747,"name":"Shalini S. Yadav","orcid":"0000-0001-8266-5548","position":20,"is_corresponding":false},{"id":1629975,"name":"Ronald Shazer","orcid":"0000-0002-0231-3436","position":21,"is_corresponding":false},{"id":845997,"name":"Hirak Der‐Torossian","orcid":"0000-0002-9902-5712","position":22,"is_corresponding":false},{"id":90470,"name":"James P. Allison","orcid":"0000-0001-8980-5697","position":23,"is_corresponding":false},{"id":90469,"name":"Padmanee Sharma","orcid":"0000-0003-4658-055X","position":24,"is_corresponding":false},{"id":226674,"name":"Nizar M. Tannir","orcid":"0000-0001-5559-8060","position":25,"is_corresponding":false},{"id":261714,"name":"Pavlos Msaouel","orcid":"0000-0001-6505-8308","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy","abstract":"<jats:p>The accumulation of immune-suppressive myeloid cells is a critical determinant of resistance to anti–programmed death-1 (PD-1) therapy in advanced clear cell renal cell carcinoma (ccRCC). In preclinical models, the tyrosine kinase inhibitor sitravatinib enhanced responses to anti–PD-1 therapy by modulating immune-suppressive myeloid cells. We conducted a phase 1-2 trial to choose an optimal sitravatinib dose combined with a fixed dose of nivolumab in 42 immunotherapy-naïve patients with ccRCC refractory to prior antiangiogenic therapies. The combination demonstrated no unexpected toxicities and achieved an objective response rate of 35.7% and a median progression-free survival of 11.7 months, with 80.1% of patients alive after a median follow-up of 18.7 months. Baseline peripheral blood neutrophil-to-lymphocyte ratio correlated with response to sitravatinib and nivolumab. Patients with liver metastases showed durable responses comparable to patients without liver metastases. In addition, correlative studies demonstrated reduction of immune-suppressive myeloid cells in the periphery and tumor microenvironment following sitravatinib treatment. This study provides a rationally designed combinatorial strategy to improve outcomes of anti–PD-1 therapy in advanced ccRCC.</jats:p>","is_dataset_classified":null,"base_score":4.219507705176107,"endowment":4.219507705176107,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"35442707","pmcid":"PMC11924199","openalex_id":"https://openalex.org/W4224224667","authors":[],"funders":[{"funder_name":"NCI NIH HHS","grant_id":"P30 CA016672","title":null}],"total_grants":1,"fwci":8.7102,"citation_percentile":0.98611757,"influential_citations":0,"citation_trend":[{"year":2022,"count":8},{"year":2023,"count":18},{"year":2024,"count":24},{"year":2025,"count":14},{"year":2026,"count":3}],"oa_status":"green","license":null,"oa_locations":[{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11924199","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11924199","host_type":"repository"},{"url":"https://www.science.org/doi/pdf/10.1126/scitranslmed.abm6420","host_type":"publisher"},{"url":"https://doi.org/10.1126/scitranslmed.abm6420","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/35442707","host_type":"repository"}],"fields_of_study":["Renal cell carcinoma treatment","Cancer Immunotherapy and Biomarkers","Renal and related cancers","Angiogenesis Inhibitors","Anilides","Carcinoma, Renal Cell","Female","Humans","Kidney Neoplasms","Liver Neoplasms","Male","Nivolumab","Pyridines","Tumor Microenvironment"],"mesh_terms":["Nivolumab","Anilides","Carcinoma, Renal Cell","Female","Humans","Kidney Neoplasms","Liver Neoplasms","Male","Pyridines","Angiogenesis Inhibitors","Tumor Microenvironment"],"keywords":["Medicine","Nivolumab","Renal cell carcinoma","Immunotherapy","Immune system","Tumor microenvironment","Oncology","Cell therapy","Clear cell renal cell carcinoma","Internal medicine","Cancer research","Immunology","Cell","Biology"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-05T18:27:27.296977Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}